These findings suggest that the regulation of purine metabolism by IMPDH2 plays an essential role in oxaliplatin resistance and provide evidence that a novel therapeutic strategy targets IMPDH2 to restore the sensitivity of CRC to oxaliplatin. Here, IMPDH2 is linked to colorectal carcinoma.